247 results on '"NAGATA, Hirohiko"'
Search Results
2. Characterizing intermediate-risk non–muscle-invasive bladder cancer: Implications for the definition of intermediate risk and treatment strategy
3. A Prospective Longitudinal Survey of Erectile Dysfunction in Patients with Localized Prostate Cancer Treated with Permanent Prostate Brachytherapy
4. The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial
5. Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer
6. Evaluation of histopathological findings at the injection site following degarelix administration
7. THE ROLE OF SINGLE INSTILLATION CHEMOTHERAPY IN PATIENTS WHO RECEIVE SUBSEQUENT BACILLUS CALMETTE-GUERIN FOR NON-MUSCLE INVASIVE BLADDER CANCER: PD11-06
8. CHARACTERIZING INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER: IMPLICATIONS FOR THE DEFINITION OF INTERMEDIATE RISK AND TREATMENT STRATEGY: MP13-17
9. Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer
10. Prognostic value of preoperative multiparametric magnetic resonance imaging (MRI) for predicting biochemical recurrence after radical prostatectomy
11. PROSPECTIVE EVALUATION OF EFFICACY AND SAFETY OF SOLIFENACIN AND MIRABEGRON TREATMENT IN BPH PATIENTS TREATED WITH DUTASTERIDE BUT HAVING OAB SYMPTOMS: PD23-11
12. ERECTILE FUNCTION IS HIGHLY ASSOCIATED WITH PROSTATE-SPECIFIC ANTIGEN BOUNCE IN LOCALIZED PROSTATE CANCER PATIENTS TREATED WITH PERMANENT PROSTATE BRACHYTHERAPY: MP32-11
13. DEVELOPMENT OF AN ALGORITHM FOR PREDICTING SEVERE ACUTE EPIDIDYMITIS: MP16-18
14. Brachytherapy with permanent seed implantation
15. Comparison of intraoperative ultrasound with postimplant computed tomography–dosimetric values at Day 1 and Day 30 after prostate brachytherapy
16. PREDICTING PROSTATE SPECIFIC ANTIGEN RECURRENCE AFTER RADICAL PROSTATECTOMY BY CLINICOPATHOLOGICAL FACTORS: SUITABILITY OF MAGNETIC RESONANCE IMAGING: 240
17. Patterns of Interstitial Lung Disease During Everolimus Treatment in Patients with Metastatic Renal Cell Carcinoma
18. Retroperitoneoscopic adrenalectomy by a lumbodorsal approach: clinical experience with solo surgery
19. MP49-16 WHO COULD BE EFFECTIVELY TREATED WITH ADJUVANT CHEMOTHERAPY AMONG PATHOLOGICALLY NODE POSITIVE MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY? : A MULTICENTER COHORT STUDY ADJUSTED BY PROPENSITY SCORE MATCHING
20. MP53-19 ANDROGEN DEPRIVATION THERAPY THROUGH THE PERI-RADIATION PERIOD REDUCES THE RISK OF BLADDER HEMORRHAGE IN PROSTATE CANCER PATIENTS UNDERGOING EXTERNAL BEAM RADIOTHERAPY
21. Contrast-enhanced Ultrasonography of the Prostate with Sonazoid
22. Prognostic Stratification in Patients Who Received Hormonal Therapy for Prostate-specific Antigen Recurrence after Radical Prostatectomy
23. PREDICTION AND STRATIFICATION OF ALPHA-BLOCKER DEPENDENCY FOLLOWING BRACHYTHERAPY IN PATIENTS WITH LOCALIZED PROSTATE CANCER: 461
24. Docetaxel in Combination with Prednisolone for Hormone Refractory Prostate Cancer
25. OPTIMIZED URINARY PH IS NECESSARY FOR THE IMPROVEMENT OF ADJUVANT MMC INSTILLATION TREATMENT FOR TUMOR RECURRENCE OF NON-MUSCLE INVASIVE BLADDER TUMORS.: 1914
26. Prostate-specific antigen ‘bounce’ after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis
27. Rectal Morbidity Following I-125 Prostate Brachytherapy in Relation to Dosimetry
28. Docetaxel‐based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration‐resistant prostate cancer: Long‐term outcomes
29. Incidence of seed migration to the chest, abdomen, and pelvis after transperineal interstitial prostate brachytherapy with loose 125I seeds
30. Preimplant factors affecting postimplant CT-determined prostate volume and the CT/TRUS volume ratio after transperineal interstitial prostate brachytherapy with 125I free seeds
31. A clinical study to evaluate the efficacy and safety of docetaxel with ribavirin in patients with progressive castration resistant prostate cancer who have previously received docetaxel alone.
32. PD48-10 PREOPERATIVE NEUTROPHIL-TO-LYMPHOCYTE RATIO AND SMOKING HISTORY ARE INDEPENDENTLY ASSOCIATED WITH BCG RELAPSING TUMOR RECURRENCE IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS
33. MP34-16 COULD ADJUVANT CHEMOTHERAPY HAVE THERAPEUTIC BENEFIT AFTER NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH EQUAL TO OR GREATER THAN PT3 MUSCLE INVASIVE BLADDER CANCER?
34. MP41-11 A PILOT CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL WITH RIBAVIRIN IN PATIENTS WITH PROGRESSIVE CASTRATION-RESISTANT PROSTATE CANCER TARGETING STEM-CELL RELATED GENE NETWORK.
35. Choriocarcinoma of the renal pelvis: a case report
36. Female Functional Constipation Is Associated with Overactive Bladder Symptoms and Urinary Incontinence
37. Obstructive sleep apnea syndrome should be considered as a cause of nocturia in younger patients without other voiding symptoms
38. PD11-06 THE ROLE OF SINGLE INSTILLATION CHEMOTHERAPY IN PATIENTS WHO RECEIVE SUBSEQUENT BACILLUS CALMETTE-GUERIN FOR NON-MUSCLE INVASIVE BLADDER CANCER
39. MP13-17 CHARACTERIZING INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER: IMPLICATIONS FOR THE DEFINITION OF INTERMEDIATE RISK AND TREATMENT STRATEGY
40. Embolization for massive retroperitoneal hemorrhage from adrenal pheochromocytoma: a case report
41. 1951 OBSTRUCTIVE SLEEP APNEA SYNDROME SHOULD BE CONSIDERED AS ONE OF CAUSES FOR NOCTURIA IN YOUNGER PATIENTS WITHOUT OTHER VOIDING SYMPTOM
42. Prostate brachytherapy seed migration to a left varicocele
43. 腎細胞癌における上皮間葉転換に着目した新規標的分子の探索
44. 301 THE IMPACT OF POSITIVE CORE DENSITY ON PREDICTION OF THE PRETREATMENT STAGE OF PROSTATE CANCER
45. Evaluation of histopathological findings at the injection site following degarelix administration
46. Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer
47. Third-line Hormonal Therapy to Treat Prostate Cancer Relapse after Initial and Second-line Hormonal Therapy: Report of 52 Cases and Literature Review
48. PD23-11 PROSPECTIVE EVALUATION OF EFFICACY AND SAFETY OF SOLIFENACIN AND MIRABEGRON TREATMENT IN BPH PATIENTS TREATED WITH DUTASTERIDE BUT HAVING OAB SYMPTOMS
49. MP32-11 ERECTILE FUNCTION IS HIGHLY ASSOCIATED WITH PROSTATE-SPECIFIC ANTIGEN BOUNCE IN LOCALIZED PROSTATE CANCER PATIENTS TREATED WITH PERMANENT PROSTATE BRACHYTHERAPY
50. MP16-18 DEVELOPMENT OF AN ALGORITHM FOR PREDICTING SEVERE ACUTE EPIDIDYMITIS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.